Last reviewed · How we verify
Personalized Smoking Cessation Pharmacotherapy
Personalized Smoking Cessation Pharmacotherapy, developed by the VA Office of Research and Development, is a marketed therapy aimed at aiding smoking cessation. The key composition patent is set to expire in 2028, providing a clear period of exclusivity. The primary risk is the lack of clear revenue data and key trial results, which may impact investor confidence and market adoption.
At a glance
| Generic name | Personalized Smoking Cessation Pharmacotherapy |
|---|---|
| Sponsor | VA Office of Research and Development |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Metabolome and Gut Microbiome Changes During Smoking Cessation in Long-term Drug Therapy in a Therapeutic Community (NA)
- Enhancing Smoking Cessation for African American People Everywhere (PHASE2)
- Effect of Early Educational Intervention on Cardiovascular Risk Factors After Acute Coronary Syndrome (NA)
- Tobacco Cessation in Public Housing (NA)
- Metabolism-informed Care for Smoking Cessation (NA)
- Smoking Cessation Pharmacotherapy-Nurse Practitioner Led Tobacco Treatment Team Study (PHASE2)
- E-cigarettes for Harm Reduction Among Smokers With Serious Mental Illness (NA)
- Digital Individualized and Collaborative Treatment of T2D in General Practice Based on Decision Aid (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: